Cardiol Posts C$29.2M Cash, C$30.2M Nine-Month Loss; MAVERIC Topline Slips to Mid-2027
CRDL sits 19% above its 52-week low of $0.88 on light trading volume (0.3× avg).
Summary
Cardiol reported C$29.2 million in cash at September 30 and a C$30.2 million nine-month loss, with runway into Q1 2028. The MAVERIC Phase III readout has slipped to mid-2027 after enrollment was expanded to about 150 patients.
Key Events · Earnings and Guidance · CRDL
-
MAVERIC Topline Pushed to Mid-2027
The Phase III recurrent pericarditis trial hit its original 110-patient target early, but the steering committee recommended expanding to about 150 patients after a blinded review showed fewer-than-expected recurrences. Target recruitment moved from Q3 to Q4 2026, and topline results are now anticipated in mid-2027.
-
Cash of C$29.2M, Runway to Q1 2028
Cash and cash equivalents were C$29,229,802 at September 30, 2026, up from C$21,416,684 at December 31, 2025. Including US$4.55 million raised under the 2026 ATM program, cash stood at C$33.2 million as of November 12, 2026, which management says funds operations into Q1 2028.
-
Nine-Month Loss Widens to C$30.2M
Net loss for the nine months was C$30,225,020 (C$0.27 per share) versus C$26,606,305 a year earlier, driven by G&A of C$15,429,919 and R&D of C$12,016,795. Operating cash use was C$16,474,840.
-
Warrant Exercises Add C$10.0M
5,387,500 warrants were exercised during the nine months for gross proceeds of C$10,047,603, leaving 325,000 derivative-classified warrants outstanding at quarter-end; after September 30, 25,000 were exercised and 300,000 expired unexercised.
Analysis · CRDL · Life Sciences
The quarter itself is unremarkable: the nine-month loss widened to C$30.2 million on higher G&A and a C$4.2 million non-cash warrant remeasurement, and the C$29.2 million cash pile (C$33.2 million as of November 12 including ATM proceeds) funds operations into Q1 2028. What matters is the trial timeline. MAVERIC hit its original 110-patient target early, but the steering committee expanded enrollment to roughly 150 because blinded review showed fewer recurrences than expected, pushing target recruitment from Q3 to Q4 2026 and topline results to mid-2027. For a company whose entire valuation rests on that readout, a delay of that length is the story, not the accounting.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDL was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.5M. The 52-week trading range was $0.88 to $2.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.